ABBV

AbbVieB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$264.73

+22.9% vs current

Most likely

Base case

60%

Probability

Target price

$227.23

+5.5% vs current

B-

Bear case

20%

Probability

Target price

$185.31

-14.0% vs current

AI sentiment snapshot

Latest data as of 2025-09-27

AI commentary

Market tone is mildly positive: analysts skew buy and median targets sit modestly above the current trade. Investors are focused on new-product execution and the durability of dividend/buyback returns; consensus upside exists but is limited. Recent price action reflects dividend support alongside cautious positioning ahead of pipeline readouts.

RankAlpha Sentiment AI - 2025-09-27

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventQuarterly earnings / guidance updateMedium impact

Q3/Q4 results and management guidance can move the stock; market watches margins and guidance post-Rinvoq/Skyrizi mix [#YahooFinance].

-catalystDividend policy & capital allocation newsMedium impact

Dividend increases or buyback changes typically support the price but are largely anticipated given high payout; surprises can still move the stock [#YahooFinance].

-catalystOncology and late-stage readouts / launchesHigh impact

AbbVie's oncology launches (e.g., Elahere, Epkinly) and registrational readouts could re-rate growth expectations if positive [#YahooFinance].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-09-27 • Updated nightlySource: Internal modelMethodology